Start-Up News September 2007
TheraCardia has a portfolio of natural biopolymers that it will develop for stents; initially, for stent coatings, and soon, a bioabsorbable stent that avoids inflammation and contributes to endothelization, without the need for a drug. Surgeon-founded Aragon Surgical will develop a platform of products to make surgeries faster and safer. Intelect Medical is developing new neurostimulation devices that, it believes, offer advances over the devices of predecessors. It's initial target application is traumatic brain injury.
You may also be interested in...
Paris-based Arterial Remodeling Technologies is developing a bioabsorbable stent that may not require the use of anti-inflammatories.
According to Medtech Insight’s recently published report, US Markets for Neurostimulation Products, the frontier for neural stimulation is expanding rapidly, representing a $628 million market in 2006 that is forecast to grow by over 20% each year to produce sales approaching $2 billion in 2012. Topics discussed include implantable pulse generators, device reimbursement, and current and emerging applications for neurostimulation.
Beyond the functional stimulation of muscles to get them moving, electrical stimulation can also operate on blood vessels, membranes, and receptors-targets in the body once regarded as the domain of pharmaceuticals. Indeed, driving sales of $2 billion in the neurostimulation industry in 2005 and growth rates of almost 20% going forward, are large-market clinical indications that haven't been well-served by drugs: pain, epilepsy, depression, stroke, urinary incontinence, Parkinson's disease, and obsessive-compulsive disorder. For some of these disorders, chronic neurostimulation-of the deep brain, the spinal cord, the vagus and other nerves-promises site-specific, side-effect free and reversible therapies that have the potential to be efficacious where drugs can't.